CBI2026: Next-Generation CGT – How Far Has It Come from Bench to Bedside?
Jinweike Biotechnology
AAV Gene Therapy New Drug Developer
Hopstem Biotechnology
iPSC Cell Therapy Product Developer
As global attention on innovative drugs shifts eastward from the JPM Conference in San Francisco, the biotherapeutics sector, led by China, is continuously accelerating its pace of innovation. Today, technological breakthroughs in the cell and gene therapy (CGT) field are emerging across multiple fronts: CAR-T technology and universal cell therapies are progressively breaking boundaries, extending from hematologic malignancies to broader therapeutic scenarios such as solid tumors and neuroimmune diseases; AAV gene therapy is accelerating its in-depth layout, continuously expanding into central nervous system (CNS) and ophthalmic indications; meanwhile, iPSC-derived therapeutics and exosome technologies are relentlessly overcoming industrialization bottlenecks, driving the industry toward large-scale and standardized development.
In this context,[CBI2026 Biopharmaceutical Innovation Expo – CGT Therapy Innovation Conference]Focusing on the implementation of cutting-edge technologies and addressing industry pain points, we precisely gather leading enterprises to create a deep, high-value industry dialogue, facilitating the transition of CGT technologies from the laboratory to clinical application, and from innovative breakthroughs to industrial implementation.
Forum Name:CBI2026 CGT Therapy Innovation Conference
Forum Schedule:September 4–5, 2026
Forum Venue:Hall B, Booth B101, Suzhou International Expo Center
*Sorted alphabetically by first letter of name; no special significance intended
Dr. Wu Tinghe is the Founder and Chief Executive Officer of Nanjing Koenris Biopharmaceutical Co., Ltd. He has long been deeply engaged in exosome-based drug loading, nucleic acid drug delivery technologies, and the development of innovative natural exosome therapeutics. Dr. Wu earned his Ph.D. in China, conducted research at the U.S. National Institutes of Health (NIH) and Stanford University, and possesses extensive experience in collaborative development with Novartis Pharmaceuticals in the field of innovative nucleic acid-based drugs.
Upon returning to China, he engaged in basic and translational research at universities and novel R&D institutions, with a focused emphasis on exosome CMC processes and industrialization pathways since 2017. In 2021, he joined Simcere Pharmaceutical Group as Senior Director of R&D, where he was responsible for building the platform for exosome drug-loading technologies. In 2023, with support from Simcere, he co-founded Nanjing Koenris Biopharmaceutical Co., Ltd. The company has completed multiple rounds of financing and facilitated external collaborations for several pipeline projects.
Chen Lijing possesses extensive experience in capital operations and corporate management within the biomedical industry, having spearheaded multiple equity financing and investment projects valued at over hundreds of millions of yuan. He currently serves as Chief Operating Officer and Vice President of Chengdu Jinweike Biotechnology Co., Ltd., where he oversees investment and financing, operational management, strategic development, and brand promotion.
With 33 years of experience in the viral vector and gene therapy industry. Involved in over 30 inventions, including: the HSV1-rc/AAV system; the AAV8-HBV1.3 murine hepatitis B model, which serves as a critical platform for the development of novel hepatitis B therapeutics; the AAV reverse infection technique; and real-time dynamic detection technology for miRNA activity profiles in living cells.
China Biopharmaceutical Industry Chain Innovation and Translation Consortium, Executive Director; Chairman of the Gene Therapy Professional Committee;
Vice Chairperson, Professional Committee on Quality Research of Cell and Gene Therapy Drugs, China Association for Pharmaceutical Quality Management;
Editorial Board Member of Progress in Pharmaceutical Sciences;
Committee Member of the Editorial Board, Chinese Journal of Medical Guide;
Zhongguancun High-End Leading Talent, Economic Development Zone “Yiqilin” Leading Talent, Daxing District “New National Gateway” Leading Talent.
Dr. Jing Fan, Founder of Hopstem Biotechnology. She holds a Bachelor’s degree from Peking University and a Ph.D. in Neuroscience from the University of British Columbia (UBC), Canada, and completed her postdoctoral research at Johns Hopkins University (JHU). She was listed among the Top 30 Global Elites in the 2018 Huachuang Elite Rankings and named one of Forbes China’s Top 50 Women in Tech in 2022. Dr. Fan has been recognized as BioCon’s Outstanding Founder of the Year and a Leading Entrepreneurial Talent in Zhejiang Province. She also serves as a member of the Cell and Gene Therapy Product Regulatory Research Committee under the Chinese Society for Drug Regulation.
Dr. Fan Jing has dedicated over two decades to the fields of iPSC-directed differentiation and neurological diseases, leading his team to secure multiple independent intellectual property rights and establish a global layout of foundational technologies. He has built a CMC and R&D platform for iPSC-derived cell products, driving the steady development of multiple disease pipelines. Notably, the flagship product, hNPC01 injection, is the first pluripotent stem cell product in China to receive Investigational New Drug (IND) approval from both Chinese and U.S. authorities. Having completed Phase I clinical trials, it has been granted FDA Fast Track designation and Regenerative Medicine Advanced Therapy (RMAT) designation, and has been approved to initiate adaptive Phase II/III clinical trials. As the globally leading iPSC-derived forebrain cell product in terms of development progress, hNPC01 holds the potential to become the Best-in-Class (BIC) therapeutic product for neural brain injury.
Education: Bachelor’s degree from Fudan University; Master’s degree from the Massachusetts Institute of Technology (MIT)
Professional Experience: Prior to joining Youyin Pharmaceuticals, Ms. Gao Lu served as Vice President at MediciBio (688202.SH), where she spearheaded R&D strategy and commercialization pathway design for Biotech clients. Previously, she held the position of Managing Director in the Financial Advisory practice at Deloitte Canada, leading cross-border investment and financing projects valued at hundreds of billions of yuan, thereby gaining comprehensive expertise in full-cycle capital operations ranging from pre-investment due diligence to post-investment exit strategies.
Upon returning to China, she has remained focused on the innovative ecosystem of biopharmaceuticals, serving in executive roles at leading pharmaceutical companies, industrial park incubators, CROs, and investment firms. She has been deeply involved in the incubation of innovative drugs, License-out transactions, cross-border business development (BD), and industrialization implementation.
Core Competencies: Over a decade of deep expertise in biopharmaceutical investment, financing, and corporate strategy, with extensive experience spanning China, the United States, and Canada, combining global perspective with local insight. Exceptional cross-cultural communication skills, adept at efficient collaboration with scientists, biopharmaceutical companies, investors, hospitals, government agencies, and other institutions. Strong resource integration capabilities and strategic thinking.
Dr. Li Zhengbin has over 10 years of experience in the field of specialized therapies, with a primary focus on ophthalmology, central nervous system disorders, rare diseases, and oncology. He has held key positions at multiple Fortune Global 500 pharmaceutical companies, including Bristol-Myers Squibb, Sanofi, Bayer, Novartis, and Johnson & Johnson. His responsibilities primarily encompassed new product commercialization, brand management, strategic planning, and strategic alliances. He successfully drove the commercial launch and brand management of more than 10 new products, achieving sustainable product growth through innovative payment solutions.
Dr. Li holds a Ph.D. from Peking Union Medical College, completed postdoctoral training at Yale University and the University of Washington, and earned an MBA from the University of Washington.
Ph.D., Beijing Science and Technology Star, leader of the “Changju Project” team, visiting scholar at Drexel University (USA), and postdoctoral fellow at the Blumberg Institute of the American Hepatitis B Foundation. He has presided over five research projects funded by the National Natural Science Foundation of China, the Beijing Natural Science Foundation, and the Beijing Municipal Science and Technology Program, and has played a core role in more than ten major national initiatives, including the National Major Science and Technology Projects, the National Key R&D Programs, and the Special Projects on Frontier Biotechnologies. He has published more than 30 high-impact academic papers in domestic and international journals and holds over ten national invention patents and computer software copyrights. Long dedicated to the research and development of innovative protein-based and cell-based therapeutics for tumor immunotherapy, he possesses extensive experience in process development and GMP manufacturing management of immune cell therapy products. He has led multiple TCR-T cell therapy products into Investigator-Initiated Trials (IIT) and registrational clinical studies, and played a pivotal role in advancing the first domestic TCR-T cell engager drug through IND submissions in both China and the United States, securing approval in both countries.
With over thirty years of experience in ophthalmic gene therapy, he graduated from the Shanghai Institute of Physiology, Chinese Academy of Sciences, where he studied under Professor Yang Xiongli, an Academician of the Chinese Academy of Sciences. He subsequently conducted postdoctoral research at Yale School of Medicine and was later promoted to Associate Research Scientist. He has secured three NIH research grants (as PI and Co-PI). In collaboration with the renowned German pharmaceutical technology company BIOLOG Life Science Institute, he helped develop and screen multiple cGMP agonists and antagonists for the treatment of retinal degenerative diseases in animal models caused by CNGA1 gene defects.
Major Academic and Professional Appointments: Joined Alcon Pharmaceuticals in the United States in 2001 as a Senior Scientist, leading the research and development of multiple drugs. Following Novartis’s acquisition of Alcon in 2010, he was invited to stay on and conducted scientific research at the Novartis R&D headquarters in Boston, receiving the company’s Spark Award for Scientific Contribution in 2012. In 2013, he served as the Technical Lead at Yingchuang Biotechnology, where he designed multiple gene therapy drugs using rAAV2 vectors, facilitating investment and collaboration from Sun Pharma on a gene therapy project for diabetic retinopathy. From 2014 to 2015, he served as Principal Scientist at Allergan Pharmaceuticals, overseeing drug development and molecular biology research for neurodegenerative and ophthalmic diseases. From 2015 to 2018, at the invitation of the Agency for Science, Technology and Research (A*STAR) and the Singapore Eye Research Institute (SERI), he served as the Overall Project Leader for the diabetic retinal hemorrhage project. Upon completion, he served as Chief Scientist at He Eye Specialist Hospital in China for two years. In May 2021, he founded Suzhou Weiyou Gene Biotechnology Co., Ltd., serving as Chairman and CEO.
Dr. Weng earned his bachelor’s degree from Peking University, his Ph.D. in Biomedical Sciences from The Chinese University of Hong Kong, and his master’s degree in Finance from the University of Macau. He is currently pursuing further studies at CEIBS (China Europe International Business School) and the School of Management, Fudan University.
In the field of scientific research, Dr. Weng served as an Assistant Professor at overseas universities and has dedicated 17 years to innovative drug development, specializing in stem cells, immune cells, and gene therapy. He has published numerous academic papers in internationally renowned journals such as Cell Stem Cell, Neuro-Oncology, Therapeutics, and Molecular Cancer, and has served as an editor or reviewer for multiple international journals. His work has been supported by major projects from the Ministry of Science and Technology of China, the National Natural Science Foundation of China, overseas funding, the Macau Science and Technology Development Fund, and the Shenzhen Science and Technology Innovation Fund.
In the field of investment, Dr. Weng previously served as Executive Director and Partner at a renowned domestic medical investment institution, successfully advancing multiple investments in innovativeBiopharmaceutical projects, with multiple projects currently undergoing IPOs.
In the industry, Dr. Weng joined several innovative biotechnology companies in China as a co-founder. He currently works full-time at Shanghai Cellive Biotechnology Co., Ltd. as Deputy General Manager, responsible for technology, process development, strategy, and financing.
Ms. Xia Jueyu currently serves as Vice President of Clinical Development at Binuozhi (Shanghai) Biotechnology Co., Ltd., where she oversees the company’s clinical development of new drugs, with a current focus on the clinical development strategy and advancement of cell therapy products such as TILs (Tumor-Infiltrating Lymphocytes) and CAR-Treg.
Prior to joining Binuoji, Ms. Xia Jueyu served as Deputy General Manager of the Clinical Medicine Center at Tuohong Kangheng Pharmaceutical Co., Ltd. During her tenure, she led the clinical development of the core product TH-SC01 stem cell injection as the project lead, successfully accelerating the project from Phase I to Phase III clinical trials within two years. In 2025, she spearheaded the translation and implementation of this product for the indication of Crohn's anal fistula as a new medical technology in Nansha, Guangzhou, completing the application approval and clinical implementation in just three months, thereby demonstrating exceptional capabilities in project advancement and translational implementation.
Ms. Xia possesses extensive experience in the clinical development and regulatory registration of innovative drugs in both China and the United States. She excels in designing comprehensive clinical development strategies for novel therapeutics and has a deep understanding of the operational and regulatory differences between the two countries. This expertise enables her to effectively oversee the entire process of clinical trial design and operations in strict adherence to regulatory requirements. Ms. Jueyu Xia has repeatedly led communications with the Center for Drug Evaluation (CDE) in China, successfully facilitating the submission of multiple Investigational New Drug (IND) applications and the approval of New Drug Applications (NDAs). Additionally, she brings practical experience in US IND submissions and clinical development, effectively empowering synchronized development and regulatory strategies for innovative drugs in both China and the United States.
Long-term commitment to research on chemical reprogramming and cell differentiation, with articles published in international academic journals such as Cell Discovery, Cell Stem Cell, and Stem Cell Transplantation Medicine.
Formerly served as Deputy General Manager of Beijing Nuowei Technology Co., Ltd. and Chief Operating Officer of Shize Biotechnology. Served as the academic leader for the stem cell safety research project at the Sichuan Provincial Key Laboratory of Primate Animal Models for Major Diseases. Possesses 14 years of academic and industry experience in the clinical translation of stem cells and regenerative medicine. In 2025, dedicated to clinical translation work, focusing on the development and clinical translational research of next-generation cell therapy technologies.
Dr. Yang Lin is the Founder, Chairman, and CEO of GenScript Biotech (Suzhou) Co., Ltd.; Chairman and CEO of GenScript Anke Cell Technology Co., Ltd.; Adjunct Professor and Doctoral Supervisor at the Tang Zhongying Hematology Research Center, Soochow University; and Director of the Suzhou Engineering Technology Research Center for Tumor Immune Diagnosis and Treatment. He previously served as an Adjunct Professor in the Department of Lymphoma/Myeloma at the University of Texas MD Anderson Cancer Center. With over 20 years of R&D experience at top-tier global cancer research centers, Dr. Yang is an expert in tumor biology and immunotherapy. He has received numerous honors, including Jiangsu Province High-Level Innovation and Entrepreneurship Leading Talent, Jiangsu Province “Six Major Peaks” Talent Team, Anhui Province Strategic Emerging Industry Technical Leading Talent, Second Prize in the China Innovation and Entrepreneurship Competition, First Place in the “Chuangxiang China” Anhui Division, Leader of the Luzhou Industrial Innovation Team, Hefei City Entrepreneurial Leading Talent, Second Prize of the Anhui Provincial Science and Technology Award, and the Winning Project Award at the National Disruptive Technology Innovation Competition Finals. He has published more than 80 academic papers in journals such as Cancer Cell, Cancer Research, Oncogene, JBC, and Cancer Science. He has led projects including those funded by the National Natural Science Foundation of China, sub-projects of the Ministry of Science and Technology’s Major Special Projects, and sub-projects of the U.S. NIH SPORE program. Dr. Yang is dedicated to the R&D of breakthrough CAR-T and CAR-γδT cell novel drugs, as well as the translational medical research and industrialization of tumor immune cell therapy technologies. He pioneered the construction in China of an internationally advanced industrialization base based on fully automated CAR-T cell production processes. Under his leadership, his team has developed multiple CAR-T cell drug candidates with first-in-class potential, targeting malignant hematologic tumors and solid tumors that are urgently needed in clinical practice.
Xue Liang Yu, Vice President of Xingrui Pharmaceutical Co., Ltd., oversees the company’s Delivery and Chemistry departments. His primary research focus is on nucleic acid delivery technologies using non-hepatotropic liposomes (LNPs) and polymer-based nanomaterials. He earned his bachelor’s degree from Tianjin University and his Ph.D. in Organic Chemistry from UT Southwestern Medical Center. He subsequently conducted postdoctoral research at the Harold C. Simmons Cancer Center at UT Southwestern. Dr. Yu has authored or co-authored more than 20 publications and patents. He possesses extensive experience in total organic synthesis, lipid synthesis, and the targeted design of LNPs.
Dr. Pi-Ming Zhao, Founder of Daoji Gene, is a leading innovator in gene therapy. He holds a bachelor’s degree from Lanzhou University, a Ph.D. from the Chinese Academy of Sciences, and completed his postdoctoral fellowship at UCSF. As a Principal Scientist in gene therapy with 15 years of focus on gene therapy and translational medicine, he led the world’s first gene therapy project for chronic kidney disease (SPLIS), secured one U.S. gene therapy patent, and delivered research benefits to international patients. With extensive industry experience in gene therapy, he excels in building efficient technology platforms and developing high-value innovative pipelines, dedicated to translating cutting-edge gene therapy technologies into clinical practice to provide affordable breakthrough therapies for patients worldwide.
Development of Next-Generation Immune Cell Therapies
Latest Research Advances in In Vivo CAR-T
Next-Generation In Vivo CAR-T Cell Therapy
Research and Development and Application of Novel CAR-T Cells
Current Status and Prospects of Universal CAR-T Development in the Field of Autoimmune Diseases
Clinical Development Progress of CAR-T Cell Therapy
The Current Status and Future of CAR-T Cell Therapy Commercialization
Process Development Challenges and Quality Management Challenges
CAR-T Therapy for Autoimmune Diseases of the Nervous System
Progress in the Development of Cell Therapy for Solid Tumors
Scalable Preparation and Application of Stem Cell-Derived Exosomes
Development Strategies for Exosomes as Delivery Vehicles for Nucleic Acid Therapeutics
Quality Control and Regulatory Considerations for the Large-Scale Production of Exosomes
Design and Engineering Strategies for Exosomes
Exploration of Exosomes in Tumor Immunotherapy
Application Prospects of Exosomes in Regenerative Medicine and Anti-Aging
Advances in Stem Cell Therapy for Tumors
Development Strategies for iPSC-Derived Cell Therapeutics
Non-Clinical Evaluation Strategy for iPSC-Derived Cell Products
Research and Development Progress of iPSC-Derived Cell Therapy Products in the Treatment of Neurological Diseases
Specifications for the Production and Quality Control of Cell-Based Pharmaceutical Products
Breakthroughs in the Manufacturing Process and Clinical Application of iPSC-Derived Cell Therapeutics
iPSC-Derived Cell Products for the Treatment of Neurological Diseases
Development Prospects and Applications of AAV Gene Therapy Drugs
Research and Development Progress of AAV for Central Nervous System Diseases
Gene Therapy Development Strategies in the Field of Rare Diseases
Innovative Development of Ophthalmic Gene Therapy Drugs
AAV Gene Therapy Product Development
The Path to Innovation and Commercialization of Gene Therapy Drugs
Development of AAV Gene Delivery Tools
Registration:
ConferenceLimited-Time Free Access(Limited spots available; registration is on a first-come, first-served basis. This is a pre-registration, and successful registration is confirmed upon approval of the application.) Accommodation and meals are at your own expense.
